Welcome to the Inaugural Dark Genome Target Discovery and Development Summit

The Dawn of the Dark Genome Has Arrived...

Significant technological advances in computational biology, next-gen sequencing, -omics platforms and AI have unlocked the transformative potential of drug discovery in the dark genome, resulting in investment and partnerships totalling over $1.5 billion in the past 6 months alone.

Designed to bring together the growing community of pioneers, the inaugural Dark Genome Target Discovery and Development Summit is the first industry-focused forum to decipher the mysteries of non-coding DNA and RNA to reveal its role in disease, while uncovering and validating novel targets across oncology, neuroscience, aging, heart disease and beyond!

Featuring a star-studded speaker line-up of ROME Therapeutics, HAYA Therapeutics, Mnemo Therapeutics, Eli Lilly and Company, HERVolution, CAMP4 Therapeutics, Nucleome, Immatics, and more, join forces with industry experts across discovery, genomics, proteomics, data science, AI, bioinformatics and computational biology to enlighten a new paradigm for drug discovery.

URLs:

Tickets: https://go.evvnt.com/2908052-2?pid=91 

Brochure: https://go.evvnt.com/2908052-3?pid=91 

Prices:

Conference + Workshop Day (3 Day Pass) - Drug Developer Pricing: USD 4197.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop Day (3 Day Pass) - Academic Pricing: USD 3597.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Workshop Day (3 Day Pass) - Solution and Service Provider Pricing: USD 5097.00,

Conference Only - Solution and Service Provider Pricing: USD 3699.00

Speakers: Adam Cribbs, Co-Founder and Chief Technology Officer, Caeruleus Genomics, Chris Burge, Whitaker Professor of Biology, Massachusetts Institute of Technology, Dan Tardiff, Vice President, Head of Discovery, CAMP4 Therapeutics, David Bumcrot, Chief Scientific Officer, CAMP4 Therapeutics, Eric Halioua, President and Chief Executive Officer, PDC*line Pharma, Generoso Ianniciello, Chief Business Officer, Anima Biotech, Hong Liu, Vice President and Head of Computational Biology, NextRNA, J. Robert Coleman, Chief Executive Officer, HERVolution Therapeutics, Jens Hukelmann, Associate Director - Target Research, Immatics, Jens Kringelum, Vice President, AI and Innovation, Evaxion Biotech, Jonathan Kwok, Chief Executive Officer and Co-Founder, Infinitopes Precision Immunomics and Oxford University, Kim Long, Vice President, Biology and Translational Sciences, ROME Therapeutics, Liyang Diao, Senior Director, Data Science, ROME Therapeutics, Matthew Maurano, Assistant Professor, Institute for Systems Genetics and Department of Pathology, NYU Medical Lab, Michael Saitakis, Director - Immunotherapy, Mnemo Therapeutics, Peter Holst, Chief Scientific Officer, HERVolution Therapeutics, Robert Salzler, Bioanalytical, Biomarker Technologies and Immunopeptidomics, Regeneron, Samir Ounzain, Chief Executive Officer and Co-Founder, HAYA Therapeutics, Shan Mandy Jiang, Senior Scientific Lead, Discovery Bioinformatics, Lilly Oncology, Eli Lilly and Co., Stephen Harrison, Chief Scientific Officer, Nucleome Therapeutics, Sudhakaran Prabakaran, CEO, NonExomics